Cyclopharm (ASX:CYC) - Managing Director and CEO, James McBrayer
Managing Director and CEO, James McBrayer
Source: Cyclopharm
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cyclopharm (CYC) has provided an update on the new drug application (NDA) for its Technegas product
  • Technegas is a lung ventilation imaging agent, which is used to assess a patient’s lung function
  • At the end of this month, the U.S. Food and Drug Administration (FDA) will begin its pre-approval audit of Cyclopharm’s manufacturing facility
  • Once this has been completed, the FDA will give Cyclopharm the product labelling requirements by early May
  • The FDA’s goal date to complete the review of the NDA is June 26 2021 and once this has been officially approved, Cyclopharm can market Technegas across the U.S.
  • Cyclopharm ended the day 9.24 per cent in the green with shares closing at $2.60

Cyclopharm (CYC) has provided an update on its new drug application (NDA) for its Technegas product.

Technegas is a lung ventilation imaging agent, which is used to assess a patient’s lung function.

The NDA was sent off to the U.S. Food and Drug Administration (FDA) and, if it’s approved, the company can market the product across the U.S.

At the end of the month, the FDA is expected to begin its pre-approval audit of Cyclopharm’s manufacturing facility. The company has reportedly been assisting the healthcare regulator with the audit by providing more information.

Once the pre-approval audit has been completed and the FDA reviews the relevant documents, it will provide Cyclopharm with the proposed labelling requirements for Technegas by early May.

The FDA’s goal date to complete the review of the NDA is June 26, 2021. Cyclopharm says this broadly aligns with its expectations and reaffirms its anticipation to commence sales early in the second half of the year.

Cyclopharm ended the day 9.24 per cent in the green with shares closing at $2.60.

CYC by the numbers
More From The Market Online
Image representing bacterial infections in the immune system

Recce reaches key dosing milestone in testing of skin infection gel

Recce Pharmaceuticals Ltd has successfully dosed 20 out of 30 participants in its Phase II trial…
Bank of England London town

Wellnex bumps first $3M payment for Pain Away into 1Q25 – when it lists in London

Wellnex Life Ltd (ASX:WNX) has unveiled its plans to defer a $2.95M payment to 360 Health…
DNA RNA therapy concept

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11,…
AI image of a scan on kidneys

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Dimerix Ltd is set to partner with a key research network at the University of Michigan…